The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Identification of Osteopontin as a Novel Marker for Early Hepatocellular Carcinoma
Open accessAbstract
The aim of this study was to identify a biomarker that could improve alpha-fetoprotein (AFP) performance in hepatocellular carcinoma (HCC) surveillance among patients with cirrhosis. We performed proteomic profiling of plasma from patients with cirrhosis or HCC and validated selected candidate HCC biomarkers in two geographically distinct cohorts to include HCC of different etiologies. Mass spectrometry profiling of highly fractionated plasma from 18 cirrhosis and 17 HCC patients identified osteopontin (OPN) as significantly up-regulated in HCC cases, compared to cirrhosis controls. OPN levels were subsequently measured in 312 plasma samples collected from 131 HCC patients, 76 cirrhosis patients, 52 chronic hepatitis C (CHC) and B (CHB) patients, and 53 healthy controls in two independent cohorts. OPN plasma levels were significantly elevated in HCC patients, compared to cirrhosis, CHC, CHB, or healthy controls, in both cohorts. OPN alone or in combination with AFP had significantly better area under the receiver operating characteristic curve, compared to AFP, in comparing cirrhosis and HCC in both cohorts. OPN overall performance remained higher than AFP in comparing cirrhosis and the following HCC groups: HCV-related HCC, HBV-associated HCC, and early HCC. OPN also had a good sensitivity in AFP-negative HCC. In a pilot prospective study including 22 patients who developed HCC during follow-up, OPN was already elevated 1 year before diagnosis. Conclusion : OPN was more sensitive than AFP for the diagnosis of HCC in all studied HCC groups. In addition, OPN performance remained intact in samples collected 1 year before diagnosis. (Hepatology 2012)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686
Self-citationThe Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
Venook, A. P., Papandreou, C., Furuse, J., & Ladrón de Guevara, L. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-s4-05 · Cited by 965
Ye, Q.-H., Qin, L.-X., Forgues, M., He, P., Kim, J. W., Peng, A. C., Simon, R., Li, Y., Robles, A. I., Chen, Y., et al. (2003) · Nature Medicine · doi:10.1038/nm843 · Cited by 850
Marrero, J. A., Feng, Z., Wang, Y., Nguyen, M. H., Befeler, A. S., Roberts, L. R., Reddy, K. R., Harnois, D., Llovet, J. M., Normolle, D., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.005 · Cited by 745
Self-citationLok, A. S., Sterling, R. K., Everhart, J. E., Wright, E. C., Hoefs, J. C., Di Bisceglie, A. M., Morgan, T. R., Kim, H., Lee, W. M., Bonkovsky, H. L., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.031 · Cited by 558
The Etiology of Hepatocellular Carcinoma and Consequences for Treatment
Sanyal, A. J., Yoon, S. K., & Lencioni, R. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-s4-14 · Cited by 517
Epidemiology of hepatocellular carcinoma in USA
El‐Serag, H. B. (2007) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00168.x · Cited by 320
Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
Villanueva, A., Minguez, B., Forner, A., Reig, M., & Llovet, J. M. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080608.100623 · Cited by 254
Pan, H., Ou, Y., Peng, S., Liu, S., Lai, P., Lee, P., Sheu, J., Chen, C., & Hsu, H. (2003) · Cancer · doi:10.1002/cncr.11487 · Cited by 251
Cited by
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
Self-citationHepatic stellate cells in liver development, regeneration, and cancer
Yin, C., Evason, K. J., Asahina, K., & Stainier, D. Y. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66369 · Cited by 719
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659
Biomarkers for the early diagnosis of hepatocellular carcinoma
Tsuchiya, N. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i37.10573 · Cited by 569
A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
Asgharpour, A., Cazanave, S. C., Pacana, T., Seneshaw, M., Vincent, R., Banini, B. A., Kumar, D. P., Daita, K., Min, H.-K., Mirshahi, F., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.005 · Cited by 538
Metadata
- Authors
- Shang, S., Plymoth, A., Ge, S., Feng, Z., Rosen, H. R., Sangrajrang, S., Hainaut, P., Marrero, J. A., & Beretta, L.
- Venue
- Hepatology
- Published
- 2012-02
- Volume
- 55
- Issue
- 2
- Pages
- 483-490
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2092589546
- Cited by
- 322
- References
- 20
- FWCI
- 11.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of Osteopontin as a Novel Marker for Early Hepatocellular Carcinoma. https://app.cochat.ai/papers/10.1002/hep.24703
- The paper
- Shang, S., Plymoth, A., Ge, S., Feng, Z., Rosen, H. R., Sangrajrang, S., Hainaut, P., Marrero, J. A., & Beretta, L. (2012). Identification of Osteopontin as a Novel Marker for Early Hepatocellular Carcinoma. Hepatology. https://doi.org/10.1002/hep.24703
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.